Home 乐动娱乐官网 Dermatology Drugs Market
dermatology drugs market

Dermatology Drugs Market [(By Therapeutic Area (Atopic Dermatitis, Psoriasis, Acne, Rosacea), By Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), By Approved Treatments (etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx), ixekizumab (Taltz), golimumab (Simponi), brodalumab (Siliq), and guselkamab (Tremfya), and By Region]: Market Size & Forecast, 2017 – 2022

  • Published Date: Feb 2018
  • Pages: 75
  • Format: PDF
  • Report ID: PM1106
  • Base Year: 2016
  • 历史数据:2015 - 2016

Report Content

The Marketed Therapies undertaken in forecast from 2016-2022 are:

  • etanercept; Enbrel
  • infliximab; Remicade
  • adalimumab; Humira
  • ustekinumab; Stelara
  • secukinumab; Cosentyx
  • ixekizumab; Taltz
  • golimumab; Simponi
  • brodalumab; Siliq
  • guselkamab; Tremfya
  • Topical Drugs
  • Oral Antibiotics

The Major Indications in Dermatology Drugs Market Therapy area:

  • Atopic Dermatitis
  • Psoriasis
  • Acne
  • Rosacea

Leading Companies investigated in the Report are

  • Allergan Plc
  • Valeant Pharmaceuticals
  • Dermira Inc
  • Aclaris Therapeutics, Inc
  • AnaptysBio, Inc
  • Revance Therapeutics
  • Foamix Pharmaceuticals
  • Novan, Inc
  • Sienna Biopharmaceuticals
  • Pfizer
  • Sanofi
  • Galderma
  • Leo Pharma
  • Roviant Sciences
  • Otsuka Pharmaceuticals
乐动体育软件最新版
Global Dermatology Drugs Market Size & Share - Industry Report, 2022